ProCE Banner Activity

Phase III MONALEESA-7: OS Analysis of Ribociclib + ET vs Placebo + ET in Pre/Perimenopausal Women With HR+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
The combination of ribociclib + initial endocrine therapy significantly prolonged median OS vs placebo + endocrine therapy in pre/perimenopausal women with HR+/HER2- advanced breast cancer.

Released: June 11, 2019

Expiration: June 09, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro